Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Verena Nowak

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Annals of Hematology|April 27, 2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Anna Hecht, Julia A Meyer, Johann-Christoph Jann, et al.
Blood|June 9, 2016
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failureMaximilian Mossner, Johann-Christoph Jann, Janina Wittig, et al.
Nature Communications|March 18, 2023
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignanciesQingyu Xu, Alexander Streuer, Johann-Christoph Jann, et al.
Haematologica|November 2, 2023
<i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasmsVladimir Riabov, Qingyu Xu, Nanni Schmitt, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Annals of Hematology|April 27, 2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Anna Hecht, Julia A Meyer, Johann-Christoph Jann, et al.
Blood|June 9, 2016
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failureMaximilian Mossner, Johann-Christoph Jann, Janina Wittig, et al.
Nature Communications|March 18, 2023
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignanciesQingyu Xu, Alexander Streuer, Johann-Christoph Jann, et al.
Haematologica|November 2, 2023
<i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasmsVladimir Riabov, Qingyu Xu, Nanni Schmitt, et al.
Pageof 5